Abstract
Here, we show that a CD40L-adjuvanted DNA/modified vaccinia virus Ankara (MVA) simian immunodeficiency virus (SIV) vaccine enhances protection against a pathogenic neutralization-resistant mucosal SIV infection, improves long-term viral control, and prevents AIDS. Analyses of serum IgG antibodies to linear peptides of SIV Env revealed a strong response to V2, with targeting of fewer epitopes in the immunodominant region of gp41 (gp41-ID) and the V1 region as a correlate for enhanced protection. Greater expansion of antiviral CD8 T cells in the gut correlated with long-term viral control.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.
Publication types
-
Research Support, N.I.H., Extramural
-
Research Support, N.I.H., Intramural
MeSH terms
-
Adjuvants, Immunologic / administration & dosage
-
Adjuvants, Immunologic / pharmacology*
-
Animals
-
CD40 Ligand / administration & dosage
-
CD40 Ligand / pharmacology
-
CD8-Positive T-Lymphocytes / immunology*
-
Epitope Mapping
-
Immunity, Cellular
-
Immunoglobulin G / blood
-
Kaplan-Meier Estimate
-
Macaca mulatta
-
SAIDS Vaccines / genetics
-
SAIDS Vaccines / immunology
-
SAIDS Vaccines / pharmacology*
-
Simian Acquired Immunodeficiency Syndrome / immunology
-
Simian Acquired Immunodeficiency Syndrome / prevention & control*
-
Vaccinia virus / genetics
-
Vaccinia virus / immunology*
Substances
-
Adjuvants, Immunologic
-
Immunoglobulin G
-
SAIDS Vaccines
-
CD40 Ligand